{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:20:07Z","timestamp":1787988007966,"version":"build-2784847793"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012669","name":"Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission","doi-asserted-by":"publisher","award":["CSTB2025NSCQ-GPX1147"],"award-info":[{"award-number":["CSTB2025NSCQ-GPX1147"]}],"id":[{"id":"10.13039\/501100012669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025MD774166"],"award-info":[{"award-number":["2025MD774166"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Postdoctoral Fellowship Program of CPSF","award":["GZC20251447"],"award-info":[{"award-number":["GZC20251447"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82325028, 92459302, and U25A20139"],"award-info":[{"award-number":["82325028, 92459302, and U25A20139"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L252055, Z220011, and Z220014"],"award-info":[{"award-number":["L252055, Z220011, and Z220014"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00259-026-08012-z","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:22:03Z","timestamp":1781652123000},"page":"6505-6519","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Improved early response assessment of chemoimmunotherapy efficacy by 68Ga-grazytracer PET\/CT in non-small cell lung cancer: a comparison of bronchial arterial versus intravenous chemotherapy"],"prefix":"10.1007","volume":"53","author":[{"given":"Xiuling","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupin","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaofei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6601-3208","authenticated-orcid":false,"given":"Hua","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"8012_CR1","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41571-025-01035-9","volume":"22","author":"S Zhao","year":"2025","unstructured":"Zhao S, Zhao H, Yang W, Zhang L. The next generation of immunotherapies for lung cancers. Nat Rev Clin Oncol. 2025;22:592\u2013616. https:\/\/doi.org\/10.1038\/s41571-025-01035-9.","journal-title":"Nat Rev Clin Oncol"},{"key":"8012_CR2","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/s41571-025-01061-7","volume":"22","author":"M Reck","year":"2025","unstructured":"Reck M, Frost N, Peters S, Fox BA, Ferrara R, Savai R, et al. Treatment of NSCLC after chemoimmunotherapy - are we making headway? Nat Rev Clin Oncol. 2025;22:806\u201330. https:\/\/doi.org\/10.1038\/s41571-025-01061-7.","journal-title":"Nat Rev Clin Oncol"},{"key":"8012_CR3","doi-asserted-by":"publisher","first-page":"217241","DOI":"10.1016\/j.canlet.2024.217241","volume":"604","author":"X Gang","year":"2024","unstructured":"Gang X, Yan J, Li X, Shi S, Xu L, Liu R, et al. Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions. Cancer Lett. 2024;604:217241. https:\/\/doi.org\/10.1016\/j.canlet.2024.217241.","journal-title":"Cancer Lett"},{"key":"8012_CR4","doi-asserted-by":"publisher","first-page":"111398","DOI":"10.1016\/j.ejrad.2024.111398","volume":"175","author":"L Lai","year":"2024","unstructured":"Lai L, Xu F, Zhang D, Chen J, Ying X, Chen L, et al. Bronchial arterial chemoembolization with Drug-Eluting beads plus sequential chemotherapy for the treatment of stage III and IV lung squamous cell carcinoma. Eur J Radiol. 2024;175:111398. https:\/\/doi.org\/10.1016\/j.ejrad.2024.111398.","journal-title":"Eur J Radiol"},{"key":"8012_CR5","doi-asserted-by":"publisher","first-page":"1591752","DOI":"10.3389\/fonc.2025.1591752","volume":"15","author":"F Zhang","year":"2025","unstructured":"Zhang F, Liu Y. Clinical study on bronchial artery chemoembolization for unresectable non-small cell lung cancer. Front Oncol. 2025;15:1591752. https:\/\/doi.org\/10.3389\/fonc.2025.1591752.","journal-title":"Front Oncol"},{"key":"8012_CR6","doi-asserted-by":"publisher","first-page":"1170344","DOI":"10.3389\/fphar.2023.1170344","volume":"14","author":"H Liu","year":"2023","unstructured":"Liu H, Li Y, Li Z, Han X, Ren K. Bevacizumab loaded CalliSpheres\u00ae bronchial arterial chemoembolization combined with immunotherapy and targeted therapy for advanced lung adenocarcinoma. Front Pharmacol. 2023;14:1170344. https:\/\/doi.org\/10.3389\/fphar.2023.1170344.","journal-title":"Front Pharmacol"},{"key":"8012_CR7","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1186\/s12885-025-13949-9","volume":"25","author":"F Tang","year":"2025","unstructured":"Tang F, Cao XJ, Gong T, Huang XY, Ya-Qing K, Xiang Z. Bronchial arterial chemoembolization\/infusion combined with iodine-125 brachytherapy in advanced non-small cell lung cancer: a promising salvage therapy after standard treatment failure. BMC Cancer. 2025;25:750. https:\/\/doi.org\/10.1186\/s12885-025-13949-9.","journal-title":"BMC Cancer"},{"key":"8012_CR8","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00330-024-11006-w","volume":"35","author":"GA Zamboni","year":"2025","unstructured":"Zamboni GA, Cappello G, Caruso D, Gourtsoyianni S, Cyran C, Schlemmer HP, et al. ESR Essentials: response assessment criteria in oncologic imaging-practice recommendations by the European Society of Oncologic Imaging. Eur Radiol. 2025;35:674\u201383. https:\/\/doi.org\/10.1007\/s00330-024-11006-w.","journal-title":"Eur Radiol"},{"key":"8012_CR9","doi-asserted-by":"publisher","first-page":"e70064","DOI":"10.1002\/cncr.70064","volume":"131","author":"I Smesseim","year":"2025","unstructured":"Smesseim I, Groot Lipman KBW, Lalezari F, Burgers JA, Trebeschi S. The legend of the response evaluation criteria in solid tumors: A historical overview. Cancer. 2025;131:e70064. https:\/\/doi.org\/10.1002\/cncr.70064.","journal-title":"Cancer"},{"key":"8012_CR10","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.2147\/cmar.S522136","volume":"17","author":"J Liu","year":"2025","unstructured":"Liu J, Xie M, Shen J, Yao J, Lin X, Bao X, et al. Advances in Multimodal Imaging Techniques for Evaluating and Predicting the Efficacy of Immunotherapy for NSCLC. Cancer Manag Res. 2025;17:1073\u201386. https:\/\/doi.org\/10.2147\/cmar.S522136.","journal-title":"Cancer Manag Res"},{"key":"8012_CR11","doi-asserted-by":"publisher","first-page":"8791","DOI":"10.1038\/s41467-024-53197-2","volume":"15","author":"X Shen","year":"2024","unstructured":"Shen X, Zhou H, Zhou X, Liu Z, Meng X, Zhang L, et al. 68Ga-grazytracer PET for noninvasive assessment of response to immunotherapy in solid tumors and lymphomas: a phase 1\/2 clinical trial. Nat Commun. 2024;15:8791. https:\/\/doi.org\/10.1038\/s41467-024-53197-2.","journal-title":"Nat Commun"},{"key":"8012_CR12","doi-asserted-by":"publisher","first-page":"e1928","DOI":"10.1002\/wnan.1928","volume":"16","author":"X Li","year":"2024","unstructured":"Li X, Chen G, Wu K, Zheng H, Tian Z, Xu Z, et al. Imaging and monitoring of granzyme B in the immune response. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024;16:e1928. https:\/\/doi.org\/10.1002\/wnan.1928.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"8012_CR13","doi-asserted-by":"publisher","first-page":"107628","DOI":"10.1016\/j.phrs.2025.107628","volume":"213","author":"B Xia","year":"2025","unstructured":"Xia B, Feng H, Jiang X, Guo J, Lin K, Zhang W, et al. Development of chimeric Nanobody-Granzyme B functionalized ferritin nanoparticles for precise tumor therapy. Pharmacol Res. 2025;213:107628. https:\/\/doi.org\/10.1016\/j.phrs.2025.107628.","journal-title":"Pharmacol Res"},{"key":"8012_CR14","doi-asserted-by":"publisher","first-page":"e161065","DOI":"10.1172\/jci161065","volume":"132","author":"H Zhou","year":"2022","unstructured":"Zhou H, Wang Y, Xu H, Shen X, Zhang T, Zhou X, et al. Noninvasive interrogation of CD8+ T cell effector function for monitoring early tumor responses to immunotherapy. J Clin Invest. 2022;132:e161065. https:\/\/doi.org\/10.1172\/jci161065.","journal-title":"J Clin Invest"},{"key":"8012_CR15","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/s1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143\u201352. https:\/\/doi.org\/10.1016\/s1470-2045(17)30074-8.","journal-title":"Lancet Oncol"},{"key":"8012_CR16","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.3390\/cells9061474","volume":"9","author":"T Flieswasser","year":"2020","unstructured":"Flieswasser T, Van Loenhout J, Freire Boullosa L, Van den Eynde A, De Waele J, Van Audenaerde J, et al. Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer. Cells. 2020;9:1474. https:\/\/doi.org\/10.3390\/cells9061474.","journal-title":"Cells"},{"key":"8012_CR17","doi-asserted-by":"publisher","first-page":"216167","DOI":"10.1016\/j.canlet.2023.216167","volume":"562","author":"F Shi","year":"2023","unstructured":"Shi F, Huang X, Hong Z, Lu N, Huang X, Liu L, et al. Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers. Cancer Lett. 2023;562:216167. https:\/\/doi.org\/10.1016\/j.canlet.2023.216167.","journal-title":"Cancer Lett"},{"key":"8012_CR18","doi-asserted-by":"publisher","first-page":"188946","DOI":"10.1016\/j.bbcan.2023.188946","volume":"1878","author":"S Yu","year":"2023","unstructured":"Yu S, Xiao H, Ma L, Zhang J, Zhang J. Reinforcing the immunogenic cell death to enhance cancer immunotherapy efficacy. Biochim Biophys Acta Rev Cancer. 2023;1878:188946. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188946.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"8012_CR19","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1021\/acs.accounts.3c00771","volume":"57","author":"C Zhao","year":"2024","unstructured":"Zhao C, Wang C, Shan W, Wang Z, Chen X, Deng H. Nanomedicines for an Enhanced Immunogenic Cell Death-Based In Situ Cancer Vaccination Response. Acc Chem Res. 2024;57:905\u201318. https:\/\/doi.org\/10.1021\/acs.accounts.3c00771.","journal-title":"Acc Chem Res"},{"key":"8012_CR20","doi-asserted-by":"publisher","first-page":"1571212","DOI":"10.3389\/fimmu.2025.1571212","volume":"16","author":"K Fang","year":"2025","unstructured":"Fang K, Yuan S, Zhang X, Zhang J, Sun SL, Li X. Regulation of immunogenic cell death and potential applications in cancer therapy. Front Immunol. 2025;16:1571212. https:\/\/doi.org\/10.3389\/fimmu.2025.1571212.","journal-title":"Front Immunol"},{"key":"8012_CR21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/imr.13251","volume":"321","author":"Y Xi","year":"2024","unstructured":"Xi Y, Chen L, Tang J, Yu B, Shen W, Niu X. Amplifying eat me signal by immunogenic cell death for potentiating cancer immunotherapy. Immunol Rev. 2024;321:94\u2013114. https:\/\/doi.org\/10.1111\/imr.13251.","journal-title":"Immunol Rev"},{"key":"8012_CR22","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1007\/s00210-023-02781-2","volume":"397","author":"A Sharma","year":"2024","unstructured":"Sharma A, Jasrotia S, Kumar A. Effects of Chemotherapy on the Immune System: Implications for Cancer Treatment and Patient Outcomes. Naunyn Schmiedebergs Arch Pharmacol. 2024;397:2551\u201366. https:\/\/doi.org\/10.1007\/s00210-023-02781-2.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"8012_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s12195-022-00742-y","volume":"15","author":"AJ Najibi","year":"2022","unstructured":"Najibi AJ, Larkin K, Feng Z, Jeffreys N, Dacus MT, Rustagi Y, et al. Chemotherapy Dose Shapes the Expression of Immune-Interacting Markers on Cancer Cells. Cell Mol Bioeng. 2022;15:535\u201351. https:\/\/doi.org\/10.1007\/s12195-022-00742-y.","journal-title":"Cell Mol Bioeng"},{"key":"8012_CR24","doi-asserted-by":"publisher","first-page":"1479483","DOI":"10.3389\/fimmu.2024.1479483","volume":"15","author":"M Skalickova","year":"2024","unstructured":"Skalickova M, Hadrava Vanova K, Uher O, Leischner Fialova J, Petrlakova K, Masarik M, et al. Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer. Front Immunol. 2024;15:1479483. https:\/\/doi.org\/10.3389\/fimmu.2024.1479483.","journal-title":"Front Immunol"},{"key":"8012_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jare.2024.03.010","volume":"69","author":"Y Han","year":"2025","unstructured":"Han Y, Jiang M, Sun Y, Chen W, Zhao Y, Guan X, et al. Efficient chemo-immunotherapy leveraging minimalist electrostatic complex nanoparticle as in situ vaccine integrated tumor ICD and immunoagonist. J Adv Res. 2025;69:169\u201379. https:\/\/doi.org\/10.1016\/j.jare.2024.03.010.","journal-title":"J Adv Res"},{"key":"8012_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/rli.0000000000001096","volume":"60","author":"G Lee","year":"2025","unstructured":"Lee G, Moon SH, Kim JH, Jeong DY, Choi J, Choi JY, et al. Multimodal Imaging Approach for Tumor Treatment Response Evaluation in the Era of Immunotherapy. Invest Radiol. 2025;60:11\u201326. https:\/\/doi.org\/10.1097\/rli.0000000000001096.","journal-title":"Invest Radiol"},{"key":"8012_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1148\/radiol.210518","volume":"306","author":"L Dercle","year":"2023","unstructured":"Dercle L, Sun S, Seban RD, Mekki A, Sun R, Tselikas L, et al. Emerging and Evolving Concepts in Cancer Immunotherapy Imaging. Radiology. 2023;306:32\u201346. https:\/\/doi.org\/10.1148\/radiol.210518.","journal-title":"Radiology"},{"key":"8012_CR28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.canlet.2021.06.028","volume":"520","author":"P Jin","year":"2021","unstructured":"Jin P, Li J, Meng Y, Wu L, Bai M, Yu J, et al. PET\/CT metabolic patterns in systemic immune activation: A new perspective on the assessment of immunotherapy response and efficacy. Cancer Lett. 2021;520:91\u20139. https:\/\/doi.org\/10.1016\/j.canlet.2021.06.028.","journal-title":"Cancer Lett"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08012-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08012-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08012-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:00:39Z","timestamp":1787986839000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08012-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8012"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08012-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This prospective clinical study received ethical approval from the institutional review board of The First Affiliated Hospital of Chongqing Medical University (Approval No. XJSYL2024110010). The trial was registered with the Chinese Clinical Trial Registry (ChiCTR2500105792). All participants provided written informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ZL is an inventor of a granted patent related to\n                      68\n                      Ga-grazytracer described in this study. The other authors declare that they have no potential conflicts of interest.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}